Global Live Biotherapeutics Products (LBPs) Market is anticipated to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of certain chronic diseases such as cardiovascular diseases, diabetes, chronic respiratory diseases, cancer, and chronic kidney disease across various countries are expected to register a lucrative growth to global live biotherapeutics products and microbe CDMO market in the forecast period. Moreover, growing preference of people around the world towards personalized medicines for physical and mental health are expected to propel the growth of live biotherapeutics products and microbe CDMO market in upcoming years.
Live Biotherapeutics Products (LBPs) are a type of therapeutic product that utilize living microbes to treat various medical conditions. Some of the commonly found at live biotherapeutics products found at in the market includes Lactobacillus acidophilus, Bifidobacterium lactis, Streptococcus thermophilus, Saccharomyces boulardii, and Escherichia coli Nissle. These microbes, such as bacteria or yeast, are typically found in the gut microbiome and play a critical role in maintaining human health. LBPs work by introducing these microbes into the body in a controlled manner to restore or enhance their function.
A Microbial Contract Development and Manufacturing Organization (CDMO) is a company that specializes in the development and manufacturing of microbial-based products, including live biotherapeutics product. Microbe CDMOs can provide a range of services, including strain development, fermentation optimization, downstream processing, and quality control. CDMO activities can be broadly categorized into three categories such as product development, manufacture of active pharmaceutical ingredients (API), and manufacture of finished dosage forms (FDF). There are around 500 Contract Development and Manufacturing Organization established in the world. Among them, Switzerland-based Lonza is the leading CDMO industry functioning across the world.
According to the report published by Pan American Health Organization (PAHO) in 2019, Ischemic heart disease accounted for 73.6 deaths per 100,000 population in the world, followed by stroke with 32.3 deaths, other circulatory diseases with 14.8 deaths, hypersensitive heart disease with 10.6 deaths, cardiomyopathy, myocarditis, and endocarditis with 5.1 deaths and rheumatic heart disease with 0.7 deaths of total population across the world.
Download Free Sample ReportRise in Demand for Personalized Medicines
Recent Developments
- In Nov 2021,Bacthera and Seres Therapeutics announced a collaboration to manufactureSER-109, Seres' lead product candidate for recurrent Clostridioides difficileinfection (CDI). Under the terms of the agreement, Bacteria is establishing adedicated facility for commercial manufacturing in its new Microbiome Center ofExcellence, a manufacturing site dedicated to the production of s located onLonza's Ibex campus in Visp, Switzerland. The agreement between Bacthera andSeres Therapeutics aims to expand upon Seres' initial commercial manufacturingsupply chain.
- In May 2021,Bacthera's drug product facility in Basel, Switzerland, and by the DanishMedicines Agency at Bacthera's drug substance facility in Hørsholm, Denmark,both facilities had been granted manufacturing licenses by the respectivenational health authorities. The permit allow the Company to fulfill the scopeof bringing innovative Live Biotherapeutic Products (LBP) to patients withunmet medical needs.
- In Nov 2019,Arranta Bio has received an US$82 million funding round and a strategicpartnership with Thermo Fisher Scientific.Through this partnersship with ThermoFisher, Arranta has access to the company's a wide range of product portfolioand services and provided materials to Thermo Fisher for use in gene therapyproduction.
- In Oct 2019, 4Dpharma plc announced research collaboration and option to license agreementwith MSD, the tradename of Merck & Co., Inc. to discover and develop LiveBiotherapeutics ("s") for vaccines. Through this agreement, 4D'sproprietary MicroRx platform will be paired with MSD's expertise in developingand commercializing novel vaccines to discover and develop s as vaccines in upto three undisclosed indications.
- In April 2019,Chr. Hansen Holding A/S and Lonza AG equally shared approximately €90m($101.5m) to establish a CDMO (contract development and manufacturingorganization) for biotherapeutic products. The investment was in two phases,bagan with an update to Lonza's existing facilities in Hørsholm, Denmark, forcGMP production of drug substances (anaerobic bacteria). It has equipped newfacilities in Basel, Switzerland, for drug product development andmanufacturing.
- In July 2022,Quay Pharma and SGS worked together to create a novel oral treatment forinflammatory bowel disease. Millions of people with Crohn's disease andulcerative colitis may make a difference in their lives because of this neworal medication. For pharmaceutical and biotechnology firms worldwide, SGS'sQuay Pharma offers a complete outsourcing service for formulation andanalytical development, followed by clinical trials and commercial manufacture.
- In June 2020, tobroaden the microbial platform and increase the flexibility of probioticmanufacturing, Chr. Hansen acquired UAS Laboratories LLC. The acquisition doesnot affect the company's ability to pay an ordinary dividend of between 40% and60% of net profit and is entirely consistent with Chr. Hansen's capital allocationpolicies. Low interest bridging financing from core banks will be used to paythe acquisition price.
- In Apr 2019,Catalent, Inc., Paragon Bioservices, Inc., and Catalent Inc. announced thatthey had signed a legally binding agreement under which Catalent would pay $1.2billion to purchase Paragon. The deal will provide Catalent's stockholders withdesirable value, and Paragon will represent a modest portion of Catalent'sbusiness in the short term. Still, over time, the acquisition will change thecompany's business profile and significantly speed up sales and EBITDA growth.
Market Segmentation
Market Players
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, Volume in tons and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Application Product Type of Formulation Scale of Operation |
| Regional scope | North America; Asia Pacific; Europe; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; China; India; Japan; Australia; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; |
| Key companies profiled | Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, Inpac Probiotics |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
